Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX), a medical device company focused on innovative technologies for diagnosing and treating nervous system diseases, has announced its participation in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024, at 4:00 PM ET. During this event, CEO Brad Hauser will provide a corporate overview and business outlook.
The event will feature a moderated discussion and allow investors to submit live questions. Autonomix will address as many questions as possible within the allotted time. A live video webcast will be available on the company's website, with a replay accessible for 90 days following the event.
Details
News Market Reaction – AMIX
The recorded move for AMIX in the trading session of this news was +9.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live webcast on Wednesday, July 24th at 4:00 PM ET
THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024 at 4:00 PM ET.
As part of the event, Brad Hauser, Chief Executive Officer of Autonomix, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Events page under the Investors section of the Company’s website (autonomix.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.